Madrigal Pharmaceuticals

Rezdiffra (resmetirom): first FDA-approved MASH treatment (March 2024, thyroid hormone receptor-beta agonist). Q1 2026 net sales $311M (+127% YoY), 42,250+ patients on therapy. Competes with GLP-1 in MASH.